Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself

Intravenous administration to human volunteers of a commercial preparation of recombinant human C-reactive protein (CRP) produced in Escherichia coli was recently reported in this journal to induce an acute phase response of serum amyloid A protein (SAA) and of CRP itself, and to activate the coagulation system. The authors concluded that CRP is probably a mediator of atherothrombotic disease. Here we confirm that this recombinant CRP preparation was proinflammatory both for mouse macrophages in vitro and for mice in vivo, but show that pure natural human CRP had no such activity. Furthermore mice transgenic for human CRP, and expressing it throughout their lives, maintained normal concentrations of their most sensitive endogenous acute phase reactants, SAA and serum amyloid P component (SAP). The patterns of in vitro cytokine induction and of in vivo acute phase stimulation by the recombinant CRP preparation were consistent with contamination by bacterial products, and there was 46.6 EU of apparent endotoxin activity per mg of CRP in the bacterial product, compared with 0.9 EU per mg of our isolated natural human CRP preparation. The absence of any proinflammatory activity in natural CRP for macrophages or healthy mice strongly suggests that the in vivo effects of the recombinant preparation observed in humans were attributable to proinflammatory bacterial products and not human CRP.

[1]  C. Sabin,et al.  Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Giddings,et al.  C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[3]  P. Reitsma,et al.  Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans , 2005, Circulation research.

[4]  Lisa M. Schwartz,et al.  Distribution of C-reactive protein values in the United States. , 2005, The New England journal of medicine.

[5]  J. Tune,et al.  C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. , 2005, American journal of physiology. Heart and circulatory physiology.

[6]  M. Singer,et al.  Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability , 2005, Circulation.

[7]  L. Rodríguez-Mañas,et al.  Evidence for Sodium Azide as an Artifact Mediating the Modulation of Inducible Nitric Oxide Synthase by C-Reactive Protein , 2005, Journal of cardiovascular pharmacology.

[8]  Carmen W van den Berg,et al.  Letter regarding article by Li et al, "C-reactive protein upregulates complement-inhibitory factors in endothelial cells.". , 2004, Circulation.

[9]  M. D. de Maat,et al.  C-reactive protein as a risk factor versus risk marker , 2004, Current opinion in lipidology.

[10]  J. Kemp,et al.  Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  S. S. Levinson,et al.  Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. , 2004, Clinical chemistry.

[12]  G. Zaloga,et al.  C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. , 2004, The American journal of medicine.

[13]  D. Lang,et al.  C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Prapat Suriyaphol,et al.  Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts Before Detrimental Terminal Sequence , 2004, Circulation.

[15]  S. Akira,et al.  Toll-Like Receptors Are Temporally Involved in Host Defense , 2004, The Journal of Immunology.

[16]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[17]  Richard D. Weisel,et al.  C-Reactive Protein Upregulates Complement-Inhibitory Factors in Endothelial Cells , 2004, Circulation.

[18]  K. Kitamura,et al.  Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. , 2004, Biochemical and biophysical research communications.

[19]  T. Horio,et al.  Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization. , 2002, Biochemical and biophysical research communications.

[20]  M. Pepys Pathogenesis, diagnosis and treatment of systemic amyloidosis. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[21]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[22]  G D Lowe,et al.  Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. , 2000, European heart journal.

[23]  M. Pepys,et al.  C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.

[24]  W. Cliff,et al.  Coronary C-reactive protein distribution: its relation to development of atherosclerosis. , 1999, Atherosclerosis.

[25]  P. Godowski,et al.  Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. , 1999, Science.

[26]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[27]  J. Starr,et al.  Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. , 1997, Age and ageing.

[28]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[29]  Y. Zhang,et al.  Plasma protein insudation as an index of early coronary atherogenesis. , 1993, The American journal of pathology.

[30]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.

[31]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[32]  S. Poole,et al.  Detection of endotoxin in mice by measurement of endotoxin‐induced changes in plasma concentrations of zinc and of the acute‐phase protein serum amyloid P‐component , 1986, The Journal of pharmacy and pharmacology.

[33]  A. Rudd,et al.  Real-time measurement of serum C-reactive protein in the management of infection in the elderly. , 1986, Age and ageing.

[34]  M. Pepys,et al.  C‐reactive protein in patients undergoing cardiac surgery , 1986, Anaesthesia.

[35]  M. Pepys,et al.  Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. , 1985, Journal of clinical pathology.

[36]  S. Poole,et al.  Effect of bacterial endotoxin on body temperature, plasma zinc and plasma concentrations of the acute-phase protein serum amyloid p component in mice. , 1984, British journal of experimental pathology.

[37]  A. Feinstein,et al.  Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins , 1984, The Journal of experimental medicine.

[38]  A. Feinstein,et al.  Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein , 1982, The Journal of experimental medicine.

[39]  A. Maseri,et al.  Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. , 1982, British heart journal.

[40]  M. Pepys,et al.  Solid phase radioimmunoassays for human C-reactive protein. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[41]  M. Pepys C-REACTIVE PROTEIN FIFTY YEARS ON , 1981, The Lancet.

[42]  D. B. Zilversmit,et al.  Transfer of Plasma Lipoprotein Components and of Plasma Proteins into Aortas of Cholesterol‐Fed Rabbits , 1981, Arteriosclerosis.

[43]  M. Pepys,et al.  Complement-independence of the acute-phase production of serum amyloijd P-component (SAP) in mice. , 1980, British journal of experimental pathology.

[44]  M. Pepys,et al.  Serum amyloid P-component is an acute-phase reactant in the mouse , 1979, Nature.

[45]  M. Pepys,et al.  Isolation and study of murine C3. , 1977, Immunology.

[46]  T. Liu,et al.  Primary structure of human C-reactive protein. , 1977, The Journal of biological chemistry.

[47]  H. Gewurz,et al.  Interactions of C-reactive protein with the complement system. II. C- reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations , 1975, The Journal of experimental medicine.

[48]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. , 1974, Journal of immunology.

[49]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.

[50]  S. Kaufmann,et al.  Studying trafficking of intracellular pathogens in antigen- presenting cells , 2002 .

[51]  P. Sansonetti,et al.  Molecular cellular microbiology , 2002 .

[52]  W. Roos,et al.  Development of a new microparticle‐enhanced turbidimetric assay for C‐reactive protein with superior features in analytical sensitivity and dynamic range , 1998, Journal of clinical laboratory analysis.

[53]  M. Pepys,et al.  In vivo turnover studies of C-reactive protein. , 1985, Clinical and experimental immunology.

[54]  C. Kindmark,et al.  Quantitative determination of individual serum proteins by radio-electroimmuno and use of 125 I-labelled antibodies (application to C-reactive protein). , 1972, Scandinavian journal of clinical and laboratory investigation. Supplementum.